Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired

Barinthus Biotherapeutics plc.

2024-Q2 EPS reported -$0.83

Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.
Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.
Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.
Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.
Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.